Article

Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.

Department of Pharmacy, Sint Maartenskliniek, PO Box 9011, 6500 GM, Nijmegen, The Netherlands.
Annals of the rheumatic diseases (Impact Factor: 9.27). 01/2008; 67(12):1697-701. DOI: 10.1136/ard.2007.083683
Source: PubMed

ABSTRACT In clinical trials only a small subset of patients with rheumatoid arthritis (RA) benefits from higher than standard dose of infliximab (>3 mg/kg/8 weeks). However, dose escalation of infliximab is frequently applied in clinical practice. Individual adjustment of infliximab treatment based on actual disease activity, instead of subjective clinical judgement, could prevent possible unwarranted dose escalation.
The infliximab dose of all patients with RA treated at our centre was decreased from 5 mg/kg to 3 mg/kg, leaving dosing intervals unaltered. Subsequently patients were followed for at least three infusions. At every visit, 28-joint Disease Activity Score (DAS28), infliximab serum trough levels and anti-infliximab antibody levels were assessed. Inversed European League Against Rheumatism (EULAR) criteria (flare criteria) were used as the endpoint.
A total of 18 patients were included in the study. Mean (SD) DAS28 scores before dose reduction and after first and second low dose were 3.2 (1.2), 3.2 (1.8) and 3.3 (1.2), respectively (values not significant). One patient (6%, 95% CI 0% to 17%) developed a persistent flare that subsided after increasing infliximab doses and one patient stopped infliximab because of a lupus-like reaction. In all other patients (n=16) lowering infliximab resulted in unaltered disease activity. Infliximab levels showed that most patients had either low- (<1 mg/litre) or high (>5 mg/litre) serum trough levels. Anti-infliximab antibodies were detected in four patients.
Infliximab dosages of 5 mg/kg can be lowered in the majority of patients with RA using DAS28-guided dose titration without increase of disease activity. Lowering the dose of infliximab should be considered in every patient receiving higher doses infliximab.

Download full-text

Full-text

Available from: Gijs F Snijders, Jul 02, 2014
2 Followers
 · 
95 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disease of the gastrointestinal (GI) tract. In the past decade a shift in the treatment paradigm of IBD has ensued. The availability of drugs capable of inducing mucosal healing, combined with the recognition that IBD is not an intermittent disease, but rather a progressive one causing bowel damage and disability, led us to a more stringent strategy. Tailored therapy with more aggressive treatment in high-risk patients, treating beyond symptoms, intervening early before damage occurs, optimizing therapeutic regimens, and actively pursuing sustained remission and sustained control of inflammation are strategies that are slowly being incorporated in our clinical practice. Furthermore, new drugs targeting different immunological pathways, such as vedolizumab, have recently been approved and therefore more therapeutic resources for patients failing anti-tumour necrosis factor alpha (anti-TNFα) agents will be available.
    05/2015; 61(3). DOI:10.1016/j.jpge.2015.03.009
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Due to ongoing developments of novel agents in the field of biological pharmacotherapy, there are now more arrows available in clinicians' quivers for the treatment of rheumatic conditions. As a consequence, however, clear treatment strategies have to be defined in order to guarantee a qualitatively high and individually stage-adapted, state-of-the-art regimen for affected patients. This review summarizes recent evidence regarding the rationale of using different biological therapies to treat rheumatoid arthritis, the most common inflammatory joint disorder after activated osteoarthritis, and draws an actual picture of a possible standardized therapeutic algorithm without claiming exclusive appropriateness.
    Arthritis research & therapy 08/2010; 12(4):214. DOI:10.1186/ar3102 · 4.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Anti-TNF drugs have proven to be effective against Spondyloarthritis (SpA), although 30% of patients fail to respond or experience adverse events leading to treatment discontinuation. In rheumatoid arthritis, the presence of anti-drug antibodies (ADA) against the first TNF inhibitor influences the outcome after switching. Our aim was to assess whether the response to a second anti-TNF is related to the previous development of ADA to the first anti-TNF drug in SpA patients. Forty two SpA patients began a second anti-TNF drug after failing to respond to the first anti-TNF. Clinical activity was assessed by Ankylosing Spondylitis Disease Activity Score (ASDAS) at baseline (at the beginning of the 1st and 2nd anti-TNF) and at 6 months after switching. The drug and ADA levels were measured by ELISA before each administration. All patients were treated with anti-TNF drugs and mainly due to inefficacy were switched to a second anti-TNF. Out of 42 patients, 11 (26.2%) developed ADA during the first biologic treatment. At baseline, no differences in ASDAS were found in patients with or without ADA to the first (3.52 +/- 1.03 without ADA vs 3.14 +/- 0.95 with ADA, P=0.399) and to the second (3.36 +/- 0.94 without ADA vs 3.09 +/- 0.91 with ADA, P=0.466) anti-TNF. At 6 months after switching, patients with previous ADA had lower disease activity (1.62 +/- 0.93 with ADA vs 2.79 +/- 1.01 without ADA, P=0.002) and most patients without ADA had high disease activity state by the ASDAS (25 out of 31 (80.6%) without ADA vs 3 out of 11 (27.3%) with ADA, P=0.002). In SpA, the failure to respond to the first anti-TNF drug due to the presence of ADA predicts a better clinical response to a second anti-TNF drug.
    Arthritis research & therapy 07/2013; 15(4):R79. DOI:10.1186/ar4258 · 4.12 Impact Factor

Similar Publications